#1 Clinical Trials Search in Europe

Study on the Effectiveness of Methylphenidate for Children and Adolescents with KBG Syndrome

1 1 1

What is this study about?

This clinical trial is focused on studying the effects of the medication methylphenidate hydrochloride in children and adolescents who have a condition called KBG syndrome. KBG syndrome is a rare genetic disorder that can cause developmental delays, distinctive facial features, and other health issues. The trial aims to determine how effective methylphenidate hydrochloride is in managing symptoms related to attention deficit and ADHD (Attention Deficit Hyperactivity Disorder) in individuals with KBG syndrome.

Participants in the study will receive either methylphenidate hydrochloride in tablet form or a placebo. Methylphenidate hydrochloride is commonly used to treat ADHD and works by affecting certain chemicals in the brain that contribute to hyperactivity and impulse control. The study will involve taking the medication orally, and the treatment period will last for a specified duration. Throughout the study, participants will be monitored for any changes in their symptoms and any potential side effects of the medication.

The purpose of this study is to gather information on the effectiveness of methylphenidate hydrochloride in improving attention and reducing ADHD-related symptoms in those with KBG syndrome. The study will use various questionnaires and assessments to evaluate the impact of the treatment on participants’ daily lives and emotional well-being. This research could provide valuable insights into managing symptoms of KBG syndrome and improving the quality of life for those affected by this condition.

1 joining the study

Participation begins after meeting specific criteria: age between 6 and 20 years, a confirmed diagnosis of KBG syndrome, and symptoms related to attention deficit or ADHD. A caregiver or supervisor must be present for reporting purposes.

2 medication administration

The study involves taking methylphenidate hydrochloride tablets. The available dosages are 5 mg and 10 mg, administered orally. The specific dosage and frequency will be determined by the study protocol.

3 monitoring and assessment

Throughout the trial, various assessments will be conducted to evaluate the effectiveness of the medication. These include the Strengths and Difficulties Questionnaire (ADHD subscale) and other tools like the SDQ emotional problems subscale and the Emotion Dysregulation Inventory reactivity index.

4 evaluation of personal goals

Participants will engage in Goal Attainment Scoring and complete a Personal Questionnaire to assess personal progress and outcomes.

5 adverse effects monitoring

An Adverse Effects checklist will be used to monitor any side effects experienced from the medication.

6 family and social assessment

The McMaster Family Assessment Device will be used to evaluate general family functioning, providing insight into the social environment of the participant.

7 completion of the trial

The trial is expected to conclude by July 1, 2027. Final assessments will be conducted to determine the overall effectiveness of the treatment.

Who Can Join the Study?

  • Age between 6 and 20 years old.
  • A confirmed diagnosis of KBG syndrome. This means having a specific change in the ANKRD11 gene or a missing piece of chromosome 16 that includes this gene.
  • Having problems with attention or symptoms related to ADHD (Attention Deficit Hyperactivity Disorder), or an official diagnosis of ADHD, which significantly affects daily life.
  • A caregiver or supervisor must be present to help provide information about the participant’s condition.

Who Cannot Join the Study?

  • Patients who do not have KBG syndrome cannot participate. KBG syndrome is a rare genetic condition.
  • Patients who are not children or adolescents are excluded. This means the study is only for young people.
  • Patients who are not experiencing attention deficit or ADHD-related symptoms cannot participate. Attention deficit means having trouble focusing, and ADHD stands for Attention Deficit Hyperactivity Disorder, which includes symptoms like being very active and having trouble paying attention.
  • Patients who are not part of the vulnerable population selected for the study cannot participate. A vulnerable population refers to groups of people who might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Slgmvdofq Rarytlb Uqeyeuibpe Mpzglsl Cqcqem Nijmegen The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Recruiting
01.06.2024

Trial locations

Investigated drugs:

Methylphenidate is a medication commonly used to treat attention deficit hyperactivity disorder (ADHD). In this clinical trial, it is being tested for its effectiveness in improving attention and reducing ADHD-related symptoms in children and adolescents with KBG syndrome. Methylphenidate works by affecting certain chemicals in the brain that contribute to hyperactivity and impulse control.

Investigated diseases:

KBG syndrome – KBG syndrome is a rare genetic disorder characterized by distinctive facial features, skeletal anomalies, and developmental delays. Individuals with this condition often have a triangular face, large upper front teeth, and short stature. The syndrome can also affect the development of bones, leading to abnormalities such as delayed bone age or short fingers. Cognitive development may be impacted, resulting in learning difficulties or intellectual disabilities. Behavioral issues, including attention deficit and hyperactivity, are common in those with KBG syndrome. The condition is caused by mutations in the ANKRD11 gene and is typically inherited in an autosomal dominant pattern.

Trial ID:
2023-506202-40-01
Protocol code:
113883
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark Italy The Netherlands Spain